Our approach
Strategy
How we intend to build a portfolio.
Exclusive licensing partnerships, targeted research and delivery innovation.
Company
From where we are to where we intend to go.
Adaptogenics Health Corp. is a public company pursuing a strategy centred on proprietary peptides, small molecules and technologies that improve their performance.
TodayWhere we intend to go
01
Public company listed on the CSE as ADPT
→Secure promising peptide assets through exclusive licensing
02
Experienced scientific and commercial leadership
→Design and optimize molecules, then test them experimentally
03
An existing nutrition and supplement business, which continues
→Improve stability, exposure and delivery
04
Evaluating potential GLP 1 companion product opportunities
→Build evidence and intellectual property that guide development
The right column describes our intent. It does not describe current capabilities, owned programs or expected results.
Areas of interest
Starting with real human needs.
These are initial areas of interest, not established clinical programs. Our ambition is broader than any single molecule or indication.
A.01
Strength and physical function
Weight loss medicines change the body. Preserving strength and physical function is an area we want to explore.
A.02
Mitochondrial function
Mitochondria power every cell. Supporting their function is a long term area of scientific interest.
A.03
Resolving inflammation
Inflammation is meant to switch off. We are exploring pathways that help it resolve.
Opportunity
Practical limits we aim to address.
Many promising molecules are held back by practical limitations rather than by their underlying biology.
- 01Stability
Peptides can break down quickly in the body or on the shelf.
- 02Biological activity
Small changes to structure can change how strongly a molecule acts.
- 03Exposure
A molecule must reach the right tissue at a useful level.
- 04Administration
Fewer barriers to use can mean broader potential reach.
AI supported design may help select and refine candidates, followed by experimental testing.
Quality and delivery
Sourcing and delivery.
- 01Sourcing and testing
Planned sourcing from qualified GMP peptide manufacturers, with independent third party testing for identity, purity and quality.
- 02Delivery platform
Delivery technologies designed to improve the stability, absorption and usability of multiple peptides, creating a broader platform opportunity.
Intelligence vision
Better molecules begin with better evidence.
We intend to connect molecular characteristics, biological activity, delivery performance and meaningful functional outcomes, so research decisions rest on connected evidence.
This is a direction we intend to build toward. It is not an operational data or AI platform, and the visual is illustrative only.
Select a node to explore.
CSE: ADPT
Follow the build.
Company overview, official releases and records, as they are verified and issued.